<p>Atea Pharmaceuticals, Inc.（纳斯达克代码：AVIR - 获取免费报告）的股票在周二交易中上涨了 5.9%。该股最高交易价为 5.40 美元，最后交易价为 5.38 美元。在午盘交易中，约有 325,173 股被交易，较平均每日交易量 671,832 股下降了 52%。该股此前收盘价为 5.08 美元。</p>
<p>获取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>另外，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Atea Pharmaceuticals 股票的 “卖出（d-）” 评级。一位股票研究分析师给予该股 “强烈买入” 评级，一位给予 “持有” 评级，另一位则给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股的平均评级为 “持有”，共识目标价为 6.00 美元。</p>
<p><strong>查看我们关于 Atea Pharmaceuticals 的最新股票报告</strong></p>
<h2>Atea Pharmaceuticals 股票上涨 5.9%</h2>
<p>该股市值为 4.2862 亿美元，市盈率为-2.77，贝塔值为 0.21。该公司的 50 日移动平均线为 4.85 美元，200 日移动平均线为 3.78 美元。</p>
<p>Atea Pharmaceuticals（纳斯达克代码：AVIR - 获取免费报告）最近于 3 月 5 日发布了季度财报。该公司报告本季度每股收益为（0.57 美元），低于市场共识预期的（0.49 美元）0.08 美元。股票研究分析师预计 Atea Pharmaceuticals, Inc.在当前年度将发布-2.01 美元的每股收益。</p>
<h2>机构投资者对 Atea Pharmaceuticals 的看法</h2>
<p>一些对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Prudential Financial Inc.在第二季度以 36,000 美元的估值购买了 Atea Pharmaceuticals 的新头寸。RFG Advisory LLC 在第四季度以 53,000 美元的价值购买了 Atea Pharmaceuticals 的股份。BNP Paribas Financial Markets 在第三季度将其在 Atea Pharmaceuticals 的股份增加了 57.7%。BNP Paribas Financial Markets 现在拥有 19,913 股该公司的股票，价值 58,000 美元，此前在上个季度又购买了 7,286 股。SG Americas Securities LLC 在第三季度以 59,000 美元的估值收购了 Atea Pharmaceuticals 的新股份。最后，Jump Financial LLC 在第四季度将其在 Atea Pharmaceuticals 的持股增加了 36.5%。Jump Financial LLC 现在拥有 19,113 股该公司的股票，价值 68,000 美元，此前在上个季度又购买了 5,106 股。86.67% 的股票由机构投资者和对冲基金持有。</p>
<h2>Atea Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Atea Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于针对 RNA 病毒的口服抗病毒治疗的发现和开发。该公司的主导项目 AT-527 是一种直接作用的核苷酸前药，已从罗氏公司获得许可，并正在评估作为 2019 冠状病毒病（COVID-19）的潜在治疗方案。除了 COVID-19 的努力外，Atea 的产品管线还包括针对丙型肝炎病毒和新兴 RNA 病原体的其他小分子候选药物，利用其专有的核苷酸化学平台来解决传染病中显著未满足的医疗需求。</p>
<p>Atea 成立于 2014 年，总部位于马萨诸塞州剑桥市，在大波士顿地区运营研究实验室，并在北美、欧洲和部分亚洲进行临床研究。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Atea Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Atea Pharmaceuticals 吗？</h2>
<p>在你考虑 Atea Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Atea Pharmaceuticals 并不在名单上。</p>
<p>虽然 Atea Pharmaceuticals 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

AVIR

<p>Atea Pharmaceuticals（纳斯达克代码：AVIR）股价在交易中上涨 5.9%，至 5.38 美元，尽管交易量较平均水平下降了 52%。分析师对该股票的评级不一，分别为一项强烈买入、一项持有和一项卖出。公司报告的季度每股亏损为（0.57 美元），未能达到预期。机构投资者持有该股票的 86.67%。Atea 专注于开发抗病毒治疗，包括针对 COVID-19 和丙型肝炎的治疗</p>

<p>Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) were up 5.9% during trading on Tuesday . The stock traded as high as $5.40 and last traded at $5.38. Approximately 325,173 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 671,832 shares. The stock had previously closed at $5.08.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc.（纳斯达克代码：AVIR - 获取免费报告）的股票在周二交易中上涨了 5.9%。该股最高交易价为 5.40 美元，最后交易价为 5.38 美元。在午盘交易中，约有 325,173 股被交易，较平均每日交易量 671,832 股下降了 52%。该股此前收盘价为 5.08 美元。</p>
</div><p>Get <strong>Atea Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Atea Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Atea Pharmaceuticals in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34; and a consensus target price of $6.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Atea Pharmaceuticals 股票的 “卖出（d-）” 评级。一位股票研究分析师给予该股 “强烈买入” 评级，一位给予 “持有” 评级，另一位则给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股的平均评级为 “持有”，共识目标价为 6.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Atea Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Atea Pharmaceuticals 的最新股票报告</strong></p>
</div><h2>Atea Pharmaceuticals Trading Up 5.9%</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 股票上涨 5.9%</h2>
</div><p>The stock has a market capitalization of $428.62 million, a P/E ratio of -2.77 and a beta of 0.21. The firm's fifty day moving average is $4.85 and its 200-day moving average is $3.78.</p>
<div class="lb-trans"><p>该股市值为 4.2862 亿美元，市盈率为-2.77，贝塔值为 0.21。该公司的 50 日移动平均线为 4.85 美元，200 日移动平均线为 3.78 美元。</p>
</div><p>Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.08). Equities research analysts expect that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current year.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals（纳斯达克代码：AVIR - 获取免费报告）最近于 3 月 5 日发布了季度财报。该公司报告本季度每股收益为（0.57 美元），低于市场共识预期的（0.49 美元）0.08 美元。股票研究分析师预计 Atea Pharmaceuticals, Inc.在当前年度将发布-2.01 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Atea Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Atea Pharmaceuticals 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. bought a new position in Atea Pharmaceuticals in the 2nd quarter valued at $36,000. RFG Advisory LLC bought a new stake in shares of Atea Pharmaceuticals during the fourth quarter worth $53,000. BNP Paribas Financial Markets increased its stake in shares of Atea Pharmaceuticals by 57.7% in the third quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company's stock valued at $58,000 after buying an additional 7,286 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Atea Pharmaceuticals in the third quarter valued at $59,000. Finally, Jump Financial LLC raised its holdings in shares of Atea Pharmaceuticals by 36.5% in the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company's stock valued at $68,000 after buying an additional 5,106 shares during the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Prudential Financial Inc.在第二季度以 36,000 美元的估值购买了 Atea Pharmaceuticals 的新头寸。RFG Advisory LLC 在第四季度以 53,000 美元的价值购买了 Atea Pharmaceuticals 的股份。BNP Paribas Financial Markets 在第三季度将其在 Atea Pharmaceuticals 的股份增加了 57.7%。BNP Paribas Financial Markets 现在拥有 19,913 股该公司的股票，价值 58,000 美元，此前在上个季度又购买了 7,286 股。SG Americas Securities LLC 在第三季度以 59,000 美元的估值收购了 Atea Pharmaceuticals 的新股份。最后，Jump Financial LLC 在第四季度将其在 Atea Pharmaceuticals 的持股增加了 36.5%。Jump Financial LLC 现在拥有 19,113 股该公司的股票，价值 68,000 美元，此前在上个季度又购买了 5,106 股。86.67% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Atea Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Atea Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company's lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea's pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.</p>
<div class="lb-trans"><p>Atea Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于针对 RNA 病毒的口服抗病毒治疗的发现和开发。该公司的主导项目 AT-527 是一种直接作用的核苷酸前药，已从罗氏公司获得许可，并正在评估作为 2019 冠状病毒病（COVID-19）的潜在治疗方案。除了 COVID-19 的努力外，Atea 的产品管线还包括针对丙型肝炎病毒和新兴 RNA 病原体的其他小分子候选药物，利用其专有的核苷酸化学平台来解决传染病中显著未满足的医疗需求。</p>
</div><p>Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.</p>
<div class="lb-trans"><p>Atea 成立于 2014 年，总部位于马萨诸塞州剑桥市，在大波士顿地区运营研究实验室，并在北美、欧洲和部分亚洲进行临床研究。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Atea Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Atea Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Atea Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Atea Pharmaceuticals 吗？</h2>
</div><p>Before you consider Atea Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Atea Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atea Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Atea Pharmaceuticals 并不在名单上。</p>
</div><p>While Atea Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Atea Pharmaceuticals 目前在分析师中获得了 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Atea Pharmaceuticals（NASDAQ:AVIR）股价上涨 5.9% - 以下是原因